Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development.
about
Molecular analysis improves pathogen identification and epidemiologic study of pediatric parapneumonic empyemaStreptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990-2010.Changing trends in serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae causing invasive diseases in Central Thailand, 2009-2012.Epidemiology of serotype 19A isolates from invasive pneumococcal disease in German childrenPneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy.Population genetic structure of Streptococcus pneumoniae in Kilifi, Kenya, prior to the introduction of pneumococcal conjugate vaccine.Serotype and genotype distribution among invasive Streptococcus pneumoniae isolates in Colombia, 2005-2010.Effects of Infant Pneumococcal Conjugate Vaccination on Serotype Distribution in Invasive Pneumococcal Disease among Children and Adults in Germany.A strain-independent method to induce progressive and lethal pneumococcal pneumonia in neutropenic miceA second-generation pneumococcal conjugate vaccine for prevention of pneumococcal diseases in children.Simultaneous identification of 29 prevalent invasive pneumococcal serotypes or pairs of serotypes by hybridization-ligation PCR.Nasopharyngeal Pneumococcal Carriage among Healthy Children in Cyprus Post Widespread Simultaneous Implementation of PCV10 and PCV13 Vaccines.Impact of pneumococcal conjugate vaccines on pneumococcal meningitis cases in France between 2001 and 2014: a time series analysis.Pneumococcal serotypes associated with invasive disease in under five children in India & implications for vaccine policy.Emerging non-PCV13 serotypes of noninvasive Streptococcus pneumoniae with macrolide resistance genes in northern JapanInvasive pneumococcal disease and 7-valent pneumococcal conjugate vaccine, the Netherlands.Changes in molecular epidemiology of streptococcus pneumoniae causing meningitis following introduction of pneumococcal conjugate vaccination in England and WalesA lactating woman presenting with puerperal pneumococcal mastitis: a case reportSerotypes and Antibiotic Susceptibility of Streptococcus pneumoniae Isolates from Invasive Pneumococcal Disease and Asymptomatic Carriage in a Pre-vaccination Period, in Algeria.Rise of multidrug-resistant non-vaccine serotype 15A Streptococcus pneumoniae in the United Kingdom, 2001 to 2014.Pneumococcal polysaccharide vaccination for adults: new perspectives for Europe.Prevnar 13, the new 13-valent pneumococcal conjugate vaccine.The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults.Use of the 13-valent pneumococcal conjugate vaccine in infants and young children.Streptococcus pneumoniae infection: a Canadian perspective.13-valent pneumococcal conjugate vaccine: a review of its use in infants, children, and adolescents.Vaccination issues in patients with chronic kidney disease.The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A.The impact of 10-valent and 13-valent pneumococcal conjugate vaccines on serotype 19A invasive pneumococcal disease.Streptococcus pneumoniae serotype 19A: Worldwide epidemiology.Necrotizing pneumonia: an emerging problem in children?Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children.Molecular characteristics of penicillin-binding protein 2b, 2x and 1a sequences in Streptococcus pneumoniae isolates causing invasive diseases among children in Northeast China.Clinical outcome of parapneumonic empyema in children treated according to a standardized medical treatment.Antimicrobial resistance, penicillin-binding protein sequences, and pilus islet carriage in relation to clonal evolution of Streptococcus pneumoniae serotype 19A in Russia, 2002-2013.Epidemiological analysis of pneumococcal serotype 19A in healthy children following PCV7 vaccination.Serotype Distribution and Antimicrobial Resistance of Streptococcus pneumoniae Invasive Isolates Collected at the Italian Hospital of Desio, Lombardy, from 2008 to 2016.Changes in pneumococcal nasopharyngeal colonization among children with respiratory tract infections before and after use of the two new extended-valency pneumococcal conjugated vaccines.Efficacy of 13-valent pneumococcal conjugate vaccine (PCV13) versus that of 7-valent PCV (PCV7) against nasopharyngeal colonization of antibiotic-nonsusceptible Streptococcus pneumoniae.Immune response to 19A serotype after immunization of 19F containing pneumococcal conjugate vaccine in Korean children aged 12-23 months.
P2860
Q30498477-AB60AB0D-08D5-43DF-A93B-2B61046361A2Q31063000-6D94B18B-CB53-48E3-98EB-9F3D53A90172Q34291155-D6866227-AB9B-41C2-AA27-0D43B26B4E0BQ34577705-2CD78681-DC3E-4C3A-9A53-25DA0A8958E1Q35016927-09325E5D-4B7A-4F3C-8D79-1F1292FFE2D7Q35055346-60C1C10B-443C-4DDB-93F1-0C1EECEEEC74Q35084987-325F53B1-EEC3-497D-BEDF-A11AF80DF657Q35679787-7875270F-1FB9-41D6-B3B7-22F93CDE38D8Q35761235-179E8A06-CFD2-41D1-97C9-5CF9DEB21CB3Q35978855-A492DB62-DC74-4CB5-8E2E-DC22E0B77296Q36022999-0EA7DFE8-7639-44E4-8796-F2E41DE1E7EBQ36153943-FFFFD0A7-FE06-41B6-88C4-B445787FDA51Q36229752-0F3A67EB-99C7-40F9-8433-9FEF0D3CBC1EQ36347414-B282ECE7-87BA-4410-8222-A0E7FED1D4F6Q36527444-D8E95238-9C9C-47D4-852C-1D317681C866Q36574279-5858D228-7EF8-46C7-821C-80ACF080CE3EQ36667552-627BC456-4340-4141-BDA5-1B007CD18AF4Q36835238-938CAC5E-59A4-466C-B3BD-6D9B42FB2DD1Q36999700-5A1F0AFA-CC4C-46B9-9B35-D7F3E034228DQ37623588-4EE574DB-21C4-4805-9623-344615904ED6Q37910264-CEC2B255-279C-4F17-A7D2-EBADDB77B735Q37951905-C254B27F-8187-4A72-A9BD-7B85A130E7A6Q37954709-6E2D27A9-B24A-48E0-AA06-02927E034CE4Q37991405-EEFCB658-B268-47E1-A8E3-CB177EFD43C0Q38131534-D31171FF-BB43-46ED-AA58-868352087027Q38137006-84344F3B-BE0E-4480-AC99-2FE9C8818AA8Q38176987-8141C109-8027-414D-A53F-87F7B46B2F99Q38366436-005D4EFB-700C-4CBE-ACA4-74449629DFE4Q38569828-7BCCDC35-A0B3-4DCF-8009-F51665041557Q38637072-57DA7F0D-A012-4E9B-8416-B17C25EDED45Q38645380-4E2F6AB3-DFAD-49E5-B59D-5CE254739760Q38956348-5A59190A-F1EF-43DD-B10E-06CD886A0AE7Q39924276-282E5B19-3E9E-41DF-8237-940A94A7AB94Q40206815-37539DDC-66EE-4414-9E02-D9C508BEBDE9Q40285306-C1DF9860-0A19-4814-9523-065329F6BA03Q40918160-87FE2480-6C3B-40D8-AAF3-E94A6B1B0B4BQ41013820-8750ADEE-BDEF-4D80-BE03-A74C0BCC49C8Q41465610-661292F2-59C9-40C0-87C7-375514DABCEFQ41684545-763D1057-3BFE-40E0-AB4E-C9E11DF9B4F9Q42136104-3CF85686-44BA-459F-88F1-66DFC24DDE13
P2860
Pneumococcal disease caused by serotype 19A: review of the literature and implications for future vaccine development.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 April 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pneumococcal disease caused by ...... or future vaccine development.
@en
Pneumococcal disease caused by ...... or future vaccine development.
@nl
type
label
Pneumococcal disease caused by ...... or future vaccine development.
@en
Pneumococcal disease caused by ...... or future vaccine development.
@nl
prefLabel
Pneumococcal disease caused by ...... or future vaccine development.
@en
Pneumococcal disease caused by ...... or future vaccine development.
@nl
P2093
P1433
P1476
Pneumococcal disease caused by ...... or future vaccine development.
@en
P2093
Michael R Jacobs
Rene Reinert
Sheldon L Kaplan
P304
P356
10.1016/J.VACCINE.2010.04.020
P407
P577
2010-04-21T00:00:00Z